Open an account

Vivos Therapeutics

VVOS · NASDAQ

$0.1406+$0.0057 (+4.23%)TodayMarket closed ·
Prev close $0.1349

About VVOS

Vivos Therapeutics, Inc. is a medical technology company which engages in the development and commercialization of treatment alternatives for patients with sleep disordered breathing (SDB). The company is headquartered in Littleton, Colorado and currently employs 268 full-time employees. The company went IPO on 2020-12-11. The firm's Complete Airway Repositioning and/or Expansion (CARE) devices are the oral appliances cleared by the United States Food and Drug Administration (FDA) for adult patients diagnosed with all severity levels of OSA (including severe OSA) and moderate-to-severe OSA in children ages 6 to 17 within the FDA cleared usage for such devices. The firm's products and services include Vivos CARE oral appliance therapy, Vivos oral appliances and therapies outside of CARE system, Vivos AireO2, Adjunctive Treatment, Treatment Navigator, Vivos Billing Intelligence Service (BIS) and Vivos Airway Intelligence Service, and others. The firm has sleep testing centers and associated medical sleep practice.

Employees
270
Headquarters
Littleton, Colorado
Listed
Dec 11, 2020
Sector
Health Care
Industry
Health Care Providers & Services
Website
vivos.com

VVOS key statistics

Market cap
4.41M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
7.70M
Volume
76.70M
Open price
$0.1307
High today
$0.1446
Low today
$0.124
52 Week high
$3.11
52 Week low
$0.1248

Vivos Therapeutics (VVOS) at a glance

As of Oct 20, 2026, Vivos Therapeutics (VVOS) shares are priced at $0.1406, giving the company a market cap of 4.41M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.124 and $0.1446. The current price is 13.4% above the day's low and 2.8% below its high.

Volume so far is 76.70M shares, above the average of 7.70M shares a day.

Over the past year Vivos Therapeutics has ranged from $0.1248 to $3.11, and now sits 1% of the way up that range.

Vivos Therapeutics met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q2 FY26 it reported -$0.31 per share against an estimate of -$0.3944.

The average analyst price target is $2.16, 1435.6% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 2 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 5 analystsAvg $2.16
Low
$0.7575
Now
$0.1406
High
$3.26

VVOS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 23.4% on average.

  1. Q3 FY24: reported -$0.40 per share against an estimate of -$0.6222
  2. Q4 FY24: reported -$0.28 per share against an estimate of -$0.4029
  3. Q1 FY25: reported -$0.45 per share against an estimate of -$0.408
  4. Q2 FY25: reported -$0.55 per share against an estimate of -$0.3927
  5. Q3 FY25: reported -$0.49 per share against an estimate of -$0.5202
  6. Q4 FY25: reported -$0.58 per share against an estimate of -$0.493
  7. Q1 FY26: reported -$0.52 per share against an estimate of -$0.4624
  8. Q2 FY26: reported -$0.31 per share against an estimate of -$0.3944

VVOS news

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Avi Kapoor

    Dow Falls Over 300 Points; SAIC Shares Jump After Upbeat Q2 Results

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • Press releaseGlobe Newswire

    Vivos’ Vida® Appliance Shows Statistically Significant Improvement in Insomnia Severity in 100% of Study Participants

  • 12 Health Care Stocks Moving In Thursday's Pre-Market Session

Similar companies

Companies in the same industry as Vivos Therapeutics

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.